Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

Tubular glucose reabsorption is performed by the combined action of Na + /D-glucose SGLTs co-transporters and GLUT-facilitated diffusion glucose transporters. SGLT2 inhibitors are a new family of ...

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...

Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

A similar treatment effect of Vanrafia was seen in an additional group of patients treated with both an RAS inhibitor and an SGLT2 inhibitor ... Price Action: NVS stock is up 2.16% at $113. ...

"Taking early, decisive action is critical to help improve ... similar in a subset of patients treated with both a RAS inhibitor and an SGLT2 inhibitor (37.4% reduction in UPCR vs placebo).